|
|
 |
|
Viewing report
|
|
|
|
Transdermal CNS Therapeutics: Products, Pipeline Candidates, Markets, Forecasts
Greystone Associates, June 2011
Current disease trends point to increasing morbidity and mortality associated with CNS ailments in the general population. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism. Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as a method that can increase patient safety and improve outcomes. In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients.
Highlights
- Analyzes and evaluates the global market opportunity for transdermal CNS drugs and assesses the probable impact of evolving regulatory, economic and demand factors
- Assesses transdermal products approved or in development for the delivery of therapeutic drugs for treating central nervous system indications
- Provides detailed descriptions of central nervous system treatment segments, market factors, and business strategies
- Forecasts transdermal CNSt product demand to 2015 by geographic region and product segment
- Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
